ClinicalTrials.gg
Not yet recruitingNCT06344936Updated Apr 3, 2024

Drug-drug Interaction Study of HRS-1780 Tablets in Healthy Subjects

A Phase 1 interventional study of HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules in Chronic Kidney Disease(CKD), sponsored by Shandong Suncadia Medicine Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 245 studies in Renal Insufficiency, Chronic with a site in China — 94 open to participants now, 107 under way, 17 of them phase 3. Renal Insufficiency, Chronic · China.

Planned enrollment
141st of 164
28 · median 182
Started
2024
with 31 others
Phase 1
20 of 245
10 open now
Primary completion
2024-07
later than 2 of 106 live
Registered
155th of 245
by date
Lead sponsor
6 of 245
Shandong Suncadia Medicine Co., Ltd.

Among the 245 studies in Renal Insufficiency, Chronic with a site in China, this one is the 141st largest by planned enrollment of the 164 interventional ones that give a count, is one of 32 that started in 2024, is one of 20 in phase 1, reaches primary completion later than 2 of the 106 other live ones, and was the 155th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

94 of the 245 studies in Renal Insufficiency, Chronic with a site in China are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Renal Insufficiency, Chronic with a site in China, or all of them as a file.
02

Study summary

The study was designed to evaluate the pharmacokinetic effects of itraconazole and rifampicin on HRS-1780 after oral administration of HRS-1780 tablets in healthy subjects

03

Conditions studied

  • Chronic Kidney Disease(CKD)
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign before the test, fully understand the test content, process and possible adverse reactions, and be willing to complete the study according to the requirements of the test plan;
  2. Healthy participants aged 18 to 45 years old (including both ends) on the date of signing the informed consent;
  3. Male participants weigh no less than 50kg, female participants weigh no less than 45kg, and (BMI) is in the range of 19.0\~26.0 kg/m2 (including the cut-off value).
  4. The participant (including the partner) does not have a family plan and voluntarily takes the measures specified in the program within 3 months after signing the informed consent letter to the last medication; Participants did not plan to donate sperm or eggs within 3 months after the end of the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Those who participated in blood donation and donated ≥400mL of blood within 3 months before taking the study drug, or received blood transfusion;
  2. Allergic constitution, including allergy related diseases (eczema, urticaria, allergic rhinitis, etc.), drug allergy or drug allergic reaction history; History of allergy to HRS-1780 tablets, itraconazole, rifampicin, rifamycin or its ;
  3. Have a history of drug and/or alcohol abuse, test positive for alcohol and drugs or have a history of drug abuse in the past five years or use of drugs in the three months prior to the test;
  4. Drinking more than 14 units of alcohol per week in the 6 months prior to screening (1 unit = 285mL for beer, 25mL for spirits, or 100mL for wine); Or have taken alcohol-containing products 48 hours before administration; Or positive alcohol breath test at baseline. ;
  5. Smoking more than 5 cigarettes per day in the 3 months before screening or use of any tobacco products 48 hours before dosing.
  6. Patients with abnormal vital signs, comprehensive physical examination, routine laboratory examination (blood routine, blood biochemistry, urine routine, coagulation function), 12-lead , chest X-ray, abdominal B-ultrasonography and judged by the investigator to be ;
  7. Medical history of major organ diseases, such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and skeletal musculoskeletal system, is not considered suitable for participation in this study;
  8. Patients with severe systemic infectious diseases, severe trauma or major surgical operations in the 3 months prior to screening and who plan to undergo surgery during the trial;
  9. Have participated in a clinical trial of any drug or medical device within 3 months or 5 half-lives prior to screening, whichever is longer, or plan to participate in a clinical trial of another drug or medical device during the trial period;
  10. Have taken any prescription or over-the-counter drugs in the 14 days prior to taking the study drug;
  11. antibody positive, antibody positive, positive, syphilis antibody positive;
  12. Women of childbearing age who have positive blood pregnancy tests at baseline;
  13. Pregnant and lactating women;
  14. Patients with a history of needle fainting and blood fainting, difficulty in blood collection or inability to tolerate venous puncture blood collection;
  15. Those who could not follow the dietary requirements during the trial;
  16. Subjects with other factors deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Group A

    Drug: HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules

Interventions

  • DrugHRS-1780 tablets; Itraconazole capsules; Rifampicin capsules

    Drug pages: HRS-1780 · Itraconazole · Rifampin

    Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice

06

What researchers measure

Primary outcomes

  1. Assess the Cmax of HRS-1780 in plasma.

    Time frame: About 3 days after the dose.

  2. Assess the Tmax of HRS-1780 in plasma.

    Time frame: About 3 days after the dose.

  3. Assess the t1/2 of HRS-1780 in plasma.

    Time frame: About 3 days after the dose.

  4. Assess the AUC0-t of HRS-1780 in plasma.

    Time frame: About 3 days after the dose.

  5. Assess the AUC0-inf of HRS-1780 in plasma.

    Time frame: About 3 days after the dose.

Secondary outcomes

  1. Assess the incidence and severity of adverse events in healthy subjects after administration of HRS-1780 tablets.

    Time frame: About a month from the first medication.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2024; primary completion for Jul 2024, 3 months later.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 3 months is below that.

Counting every sponsor, half of 109 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Apr 3, 2024
StartEst.
Apr 2024
Primary completionEst.
Jul 2024
CompletionEst.
Jul 2024
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06344936
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Apr 2024 (estimated)
Primary completion
Jul 2024 (estimated)
Completion
Jul 2024 (estimated)
Last update
Apr 3, 2024

Study contacts

Na Li
Contact
na.li@hengrui.com
+86- 15618362889
Weilin Qian
Contact
weilin.qian@hengrui.com
+86-13621800915

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HRS-1780 · Itraconazole · Rifampin

Start the discussion